The omics era demands unbiased, discovery-first approaches, moving from single targets to full proteomes. In spatial proteomics, traditional tools limit scientists to known proteins, leaving critical biology unexplored. The Microscoop® platform from Syncell overcomes this barrier, enabling microscopy-guided isolation of proteins at single-cell and subcellular resolution. Its dried-down, transportable samples are compatible with any mass spectrometer, providing complete proteome coverage and delivering insights into tissue and cellular organization without target restrictions. With a current resolution of 350 nm and development toward sub-100 nm, Microscoop is transforming spatial proteomics for drug discovery, neurological research, and cell biology.
Recent studies highlight the platform’s potential for breakthrough discoveries. At the University of Stuttgart, researchers used Microscoop to map proteins in nuclear bodies linked to triple-negative breast cancer metastasis, identifying novel proteins whose disruption prevented metastatic phenotypes. At the Mayo Clinic, the platform enabled an unbiased characterization of protein aggregates in ALS, expanding understanding beyond single proteins like TDP-43. By providing a hypothesis-free, high-resolution view of proteins in precise locations, Microscoop accelerates biomarker discovery, therapeutic target identification, and translational research, ensuring critical proteins and pathways are no longer missed.
👉 Read the full article “Spatial Proteomics Has a Discovery Problem” on Genetic Engineering & Biotech News
